Prof. David Marks 🇬🇧
He is a Professor and Co-Section Head of AML at MD Anderson Cancer Center, specializing in molecular and immune therapies for AML and MDS.
He is a world-renowned clinical investigator with 500+ publications and extensive experience leading international clinical trials in leukemia.
10:20 – 10:50
FRIDAY - 4TH SEPTEMBER Day 1
Allogeneic HSCT for adults with ALL: Rationale, recent trials and current practice